Driven by natural ingredient demand and infection prevention technologies, the skin repair sector faces challenges in product efficacy and consumer trust. Gender-neutral solutions emerge as a key ...

According to a Phase 3 clinical trial (INTEGUMENT-PED) roflumilast cream 0.05% is effective and safe for children aged 2-5 ...

Orismilast may be an effective and safe novel treatment option for adult patients with moderate to severe atopic dermatitis.

Arcutis Biotherapeutics (ARQT) announced that Pediatric Dermatology published online positive results from INTEGUMENT-PED, the pivotal phase 3 ...

TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK, Feb. 24, 2025 /PRNewswire/ ...

Almirall as European leader in Medical Dermatology: we delivered impactful products to more patients and the medical community. Our double-digit sales growth and increased profitability demonstrate ...

The FDA has cleared an Investigational New Drug Application for Zabalafin Hydrogel, a multi-target therapy for mild to ...